SUMMARY A group of 202 patients with suspected, probable or definite multiple sclerosis was studied, using cranial computed tomography (CT). Atrophy alone, or in combination with whitematter and periventricular lucencies, and areas of contrast enhancement, were the main abnormal findings in 52% of patients. Atrophy was detected in 44% of patients, and its frequency and severity correlated with disease duration up to 10 years, age, and disease category. Atrophic changes in the brainstem and cerebellum could be correlated with clinical data more often than supratentorial atrophy could be correlated with features such as dementia or mood changes. Lucencies in the white matter, thought to represent areas of demyelination, were noted in 21 % of patients, and only a proportion of these lesions could be correlated with clinical data, the others being clinically silent. Contrast enhancement was seen in a small proportion of white-matter lesions, and was independent of disease activity and steroid medication. Electrophysiological tests and cerebrospinal fluid analysis showed a higher yield of abnormality than CT scanning in cases with suspected or possible multiple sclerosis, though in such patients CT scanning excluded alternative cerebral atrophy. Modifications of the technique of CT scanning may improve the detection rate of white-matter lesions, thereby enhancing the value of CT as a diagnostic tool in the study of patients with multiple sclerosis.
Cranial computed tomography (CT) has been used in the investigation of patients with diseases of the white matter, including multiple sclerosis.1-7 The main abnormalities detected in CT scans of patients with multiple sclerosis are atrophy and areas of low attenuation, with or without enhancement, interpreted as plaques. The results of the series reported so far have been rather variable, and the diagnostic usefulness of CT has been questioned, especially in the early or suspected cases ol multiple sclerosis. The enhancement characteristics of "plaques" have been reported in a small number of patients only, again with variable and conflicting results. The present investigation was undertaken both as a retrospective and prospective assessment of the value of CT in the management of patients with multiple sclerosis. The various types of abnormality were identified and correlated with the clinical data at the time of CT scanning. The specificity of these abnormalities was assessed, and their usefulness was compared with other standard investigations, namely cerebrospinal fluid analysis, and visual and auditory evoked potentials.
Patients and methods
All 202 patients in this study had been 2) . Contrast enhancement was noted in white-matter areas in seven patients; in three there were no unenhanced scans for comparison; in the others, low attenuation areas showed uniform or peripheral contrast enhancement; in two of the latter patients, radionuclide scans showed increased uptake of technetium in areas corresponding to the enhancing lesions. There was no correlation between contrast enhancing lesions and disease activity; six patients with enhancing WML were in exacerbation, compared with 15 others who did not show enhancement of their WML. Complete resolution of a contrast-enhancing lesion was noted in one patient.
The incidence of white-matter and/or periventricular lucencies in patients in clinical exacerbation was 23%, compared with 18% for patients in remission or stable disease activity: the difference is not significant. The incidence of lucencies in patients over the age of 40 was 31%, compared with 13-5% for patients under the age of 40, the differences being significant (p < 0 01). A significant difference (p < 0-01) was also found in the incidence of WML and PVL in patients with disease duration over five years. In the 56 patients with moderate or severe disability, the incidence of 
Discussion
This study has established that the cranial CT features of multiple sclerosis are atrophy, areas of whitematter low attenuation, and areas of abnormal contrast enhancement. It has also provided some epidemiological data on a large hospital group of multiple sclerosis patients. Cerebral atrophic changes, occurring alone or in combination with other lesions, were seen in 44% of our patients. It was established that the incidence of atrophy is greater in all age groups of multiple sclerosis patients compared with controls; that there is an increase in the incidence of atrophy with advancing disease category; that most atrophic changes occur during the first 10 years of the disease; and that thereafter the increased incidence of atrophy does not reach statistical significance within the multiple sclerosis group. Cala et al3 observed the same positive relationship between atrophy and age, disease duration and category, in their 100 patients, their overall figure for the incidence of atrophy being 44%. Other authors ' 6 on the other hand did not find such a correlation, most probably because they confined their studies to patients with long-standing "definite" or "highly probable" multiple sclerosis. The incidence of atrophy as reported in other series ranges between 21% and 72%, reflecting either the relatively small number of patients studied, or the predominance of patients with definite multiple sclerosis in the series. l 6 9-12 Atrophic changes alone were seen in 64 patients in this series, while atrophy in combination with whitematter and periventricular lucencies was present in 25; in the latter patients-21 of whom had definite multiple sclerosis, the extent of atrophy was greater, supporting the neuropathological findings of Brownell and Hughes'3 that there is a close association between ventricular dilatation and the number and size of multiple sclerosis plaques. Infratentorial atrophic changes were found to correlate with clinical data of brainstem or cerebellar dysfunction in a significant proportion of our patients: this is a reflection of the close relationship between structure and function in these areas of the brain, and of their frequent involvement in multiple sclerosis (68% of all patients in this series). Cortical atrophy with ventricular dilatation has been reported to correlate with dementia in a small group of multiple sclerosis patients studied by Cf;5 similar observations were made by Barnard and Triggs 14 in their neuropathological study of 20 multiple sclerosis patients.
Such correlation was also seen in the present study, in that all the 14 patients who had dementia or mood changes showed supratentorial atrophy on CT, while no patients with mental changes were found in the group with normal CT scans. In general the presence of atrophic changes is a significant diagnostic observation in patients with a clinical profile suggestive of multiple sclerosis, although such changes are in no way qualitatively different from those found in patients with other disease processes. '`" The discriminant value of atrophy is, however, increased in the presence of white-matter lucencies and areas of contrast enhancement.
In the present series more lucencies were encountered in the central white matter than in the immediate periventricular region (49 vs 15, in 41 patients). ' 9 The white-matter lucencies occurred both as acute symptomatic and as silent lesions, while the periventricular lucencies were all clinically silent.2 6Lucencies were found mainly in patients with definite multiple sclerosis occurring either alone (16 patients), or in combination with atrophy (25 patients).' 3 6 18 The relatively low incidence of lucencies in the present series may be due to the routine use of 13 mm or 10 mm cuts; whereas because of their mainly small size, white-matter lucencies are better seen in 8 mm or 5 mm cuts. ' 3 19-21 Enhancement of the CT scan did not result in demonstration of a substantially greater number of abnormal areas in the white matter. and 80% respectively in the latter study.4' The classification of patients according to clinical criteria alone resulted in the relatively lower figure (39%) for the definite category compared with the 50% figure in the French study,4' which took into consideration laboratory results. The majority of our patients had no or only mild disability (5% and 67% respectively), moderate disability affecting 23%, and severe disability 5% of patients. The percentage of abnormal scans in these four functional groups was 0%, 53%, 50% and 90% respectively. It was interesting to note that within the definite multiple sclerosis category there were more abnormal scans in patients with mild disability than in patients with moderate and severe disability combined (87% vs 56%, p < 0-01). At present, therefore, the CT scan can only discriminate between patients with no disability, some disability, and severe disability, but cannot be used reliably as an indicator of prognosis.
Comparison of the standard CT scan with CSF examination and electrophysiological tests showed that the latter investigations were superior in detecting abnormalities in the possible or suspected cases of multiple sclerosis. This is at variance with the results of another study" on 33 patients, 10 of whom had the diagnosis of possible multiple sclerosis supported by CT. In this category, the value of CT scanning lies in the fact that it excludes alternative structural pathology, and may also demonstrate relevant white-matter lesions in individual patients. In patients with probable or definite multiple sclerosis, the CT scan provides as much information as the CSF analysis and electrophysiological tests, but in addition it provides direct evidence of dissemination of lesions in various parts of the neuraxis.' A similar conclusion could be drawn from a study of 72 patients with chronic progressive myelopathy investigated by CSF analysis, neurophysiological tests, and CT. 42 Further improvements in the resolution of CT scanners may make it possible to detect lesions in the brainstem, optic nerves, and spinal cord43 with greater accuracy, thus enhancing the value of CT as a diagnostic tool in multiple sclerosis, though it may be supplanted by nuclear magnetic resonance imaging, when this facility becomes widely available. 4 
